Skip to Content

'
Arlene O Siefker-Radtke, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Clinical Co-Leader, Bladder SPORE Executive Committee, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3508
Phone: (713) 792-2830
Fax: (713) 745-0422
Email: asiefker@mdanderson.org

Education & Training

Degree-Granting Education

1996 The Johns Hopkins University School of Medicine, Baltimore, MD, MD, Medicine
1992 Michigan State University, East Lansing, MI, BS, Biochemistry

Postgraduate Training

7/1999-6/2002 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert Wolff, M.D.
6/1996-6/1999 Clinical Residency, Internal Medicine, New England Medical Center Hospital, Boston, MA

Board Certifications

11/2002 Medical Oncology
8/1999 Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2002-8/2010

Administrative Appointments/Responsibilities

Committee Chair, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center Clinical Research Committee, Houston, TX, 2006-2009
Disease Site Liaison to the International Center, International Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2005-present

Institutional Committee Activities

Member, Data Safety Monitoring Board, 2010-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining Patient Selection for Neoadjuvant Chemotherapy Prior to Radical Cystectomy. J Urol 191(1):40-7, 1/2014. e-Pub 7/30/2013. PMID: 23911605.
2. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic down-staging and long-term outcomes. Results from a retrospective study at the M.D. Anderson Cancer Center. Eur Urol 64(2):307-13, 8/2013. e-Pub 4/17/2012. PMCID: PMC3815632.
3. Galsky MD, Hendricks R, Svatek R, Bangs R, Hoffman-Censits J, Clement J, Dreicer R, Guancial E, Hahn N, Lerner SP, O'Donnell PH, Quale DZ, Siefker-Radtke A, Shipley W, Sonpavde G, Vaena D, Vinson J, Rosenberg J. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: A report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer 119(11):1994-8, 6/1/2013. e-Pub 3/1/2013. PMID: 23456777.
4. Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, Siefker-Radtke AO. Plasmacytoid Urothelial Carcinomas - A Chemo-sensitive Cancer with Poor Prognosis, and Peritoneal Carcinomatosis. J Urol 189(5):1659 - 1661, 5/2013. e-Pub 11/15/2012. PMID: 23159581.
5. Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A Phase 2 Clinical Trial of Sequential Neoadjuvant Chemotherapy With Ifosfamide, Doxorubicin, and Gemcitabine Followed by Cisplatin, Gemcitabine, and Ifosfamide in Locally Advanced Urothelial Cancer. Cancer 119(3):540-7, 2/1/2013. e-Pub 8/22/2012. PMCID: PMC3828072.
6. Tran MN, Choi W, Wszolek MF, Navai N, Lee IL, Nitti G, Wen S, Flores ER, Siefker-Radtke A, Czerniak B, Dinney C, Barton M, McConkey DJ. The p63 isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: Role of miR205. J Biol Chem 288(5):3275-3288, 2/1/2013. e-Pub 12/13/2012. PMCID: PMC3561548.
7. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma-Neoadjuvant and Adjuvant Settings. Eur Urol 63(1):58-66, 1/2013. e-Pub 8/14/2012. PMID: 22917984.
8. Qi W, White MC, Choi W, Guo C, Dinney C, McConkey DJ, Siefker-Radtke A. Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. PLoS One 8(7):e69509, 2013. e-Pub 7/2013. PMCID: PMC3715471.
9. Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC. Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas MD Anderson Cancer Center experience. Urol Oncol 30(6):879-85, Nov-Dec, 11/2012. e-Pub 10/8/2010. PMCID: PMC3956468.
10. Marquis L, Tran M, Choi W, Lee IL, Huszar D, Siefker-Radtke A, Dinney C, McConkey DJ. p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol Ther 13(7):477- 486, 5/2012. e-Pub 5/1/2012. PMCID: PMC3958424.
11. Alva AS, Matin SF, Lerner SP, Siefker-Radtke AO. Perioperative chemotherapy for upper tract urothelial cancer. Nat Rev Urol 9(5):266 - 273, 5/2012. e-Pub 4/10/2012. PMID: 22487872.
12. Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, Yu D, Adam L, Wen S, Shen Y, Dinney C, McConkey DJ, Siefker-Radtke A. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One 7(1):e30206, 2012. e-Pub 1/2012. PMCID: PMC3254658.
13. Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP, Matin SF. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology 78(1):61-7, 7/2011. e-Pub 2/26/2011. PMCID: PMC3118266.
14. Black PC, Dinney CP, Brown GA, Kassouf W, Siefker-Radtke AO, Munsell MF, Grossman HB, Kamat AM. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol 29(2):157-161, Mar-Apr, 3/2011. e-Pub 4/2010. PMCID: PMC2950900.
15. Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Ficarra V, Sagalowsky AI, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 16(17):4461-7, 9/2010. e-Pub 7/2010. PMID: 20651056.
16. Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116(13):3127-34, 7/1/2010. PMID: 20564621.
17. Siefker-Radtke A. Bladder cancer: can we move beyond chemotherapy? Curr Oncol Rep 12(4):278-83, 7/2010. PMID: 20446067.
18. McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke A, Dinney C, Czerniak B. Molecular genetics of bladder cancer: Emerging mechanisms. Urol Oncol 28(4):429-40, Jul-Aug, 7/2010. PMCID: PMC2901550.
19. Childs MA, Wood CG, Spiess, PE, Debiane L, Hernandez M, Matin S, Millikan R, Siefker-Radtke A, Scott SM, Pisters LL. Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy. The Canadian Journal of Urology 17(3):5184-5189, 6/2010.
20. Logothetis CJ, Siefker-Radtke A. Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Eur Urol 57(4):728-9, 4/2010. PMID: 20965043.
21. Hussain MH, Wood DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, O'Donnell MA, Siefker-Radtke AO, Theodorescu D, Dinney CP. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol 27(34):5680-4, 12/1/2009. e-Pub 10/26/2009. PMID: 19858384.
22. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28(3-4):335-44, 12/2009. PMID: 20012924.
23. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C. miR-200 expression regulates epithelial to mesenchymal transition in bladder cancer cells and reverses resistance to EGFR therapy. Clin Cancer Res 15(16):5060-72, 8/15/2009. e-Pub 8/11/2009. PMID: 19671845.
24. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 27(16):2592-7, 6/1/2009. e-Pub 5/4/2009. PMID: 19414678.
25. Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73(1):147-52, 1/2009. e-Pub 10/9/2008. PMCID: PMC2674246.
26. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180(3):867-72; discussion 872, 9/2008. e-Pub 7/17/2008. PMID: 18635226.
27. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 14(5):1478-86, 3/1/2008. PMID: 18316572.
28. Siefker-Radtke AO. Metastatic squamous cell carcinoma of the urachus: review. Clinical Advances in Hematology & Oncology 5(11):887-90, 11/2007.
29. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, Kamat AM. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol 52(3):769-74, 9/2007. e-Pub 4/10/2007. PMCID: PMC2691552.
30. Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M. D. Anderson Cancer Center experience. Cancer 110(4):764-9, 8/15/2007. PMID: 17614317.
31. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of The University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62-7, 7/1/2007. PMID: 17542024.
32. Siefker-Radtke A. Urachal carcinoma:surgical and chemotherapeutic options. Expert Rev Anticancer Ther 6(12):1715-21, 12/2006. PMID: 17181485.
33. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107(9):2254-61, 11/1/2006. PMID: 17029276.
34. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107(3):497-505, 8/1/2006. PMID: 16795067.
35. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson cancer center experience. J Urol 175(6):2058-62, 6/2006. PMID: 16697803.
36. Siefker-Radtke AO. Systemic chemotherapy options for metastatic bladder cancer. Expert Rev Anticancer Ther 6(6):877-885, 6/2006. PMID: 19954279.
37. Siefker-Radtke A. Systemic chemotherapy options for metastatic bladder cancer. Expert Rev Anticancer Ther 6(6):877-85, 6/2006. PMID: 16761931.
38. Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology 46(1):57-63, 1/2005. PMID: 15656887.
39. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 172(2):481-4, 8/2004. PMID: 15247709.
40. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell 6(2):111-6, 8/2004. PMID: 15324694.
41. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 171(1):145-8, 1/2004. PMID: 14665863.
42. Millikan R, Siefker-Radtke A, Grossman HB. Neoadjuvant chemotherapy for bladder cancer. Urol Oncol 21(6):464-7, Nov-Dec, 11/2003. PMID: 14693274.
43. Sweeney P, Millikan R, Donat M, Wood C, Siefker Radtke AO, Pettway C, Grossman HB, Dinney C, Swanson D, Pisters L. Is there a role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169(6):2113-7, 6/2003. PMID: 12771730.
44. Siefker-Radtke AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, Pisters LL. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol 169(4):1295-8, 4/2003. PMID: 12629346.
45. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20(5):1361-7, 3/1/2002. PMID: 11870180.
46. Hsi LC, Tsai AL, Kulmacz RJ, English DG, Siefker AO, Otto JC, Smith WL. Trp387 and the putative leucine zippers of PGH synthases-1 and -2. J Lipid Mediators 6(1-3):131-138, 3/1993. PMID: 8357979.

Invited Articles

1. Siefker-Radtke A. Urachal Adenocarcinoma: A Clinician's Guide for Treatment. Semin Oncol 39(5):619-624, 10/2012. PMID: 23040259.

Editorials

1. Siefker-Radtke A. Dose-dense makes sense: Emerging concepts in urothelial cancer. Genitourinary Cancers Symposium Daily News(1):18, Feb 18, 2011, 2/2011.
2. Logothetis CJ, Siefker-Radtke A. Re: Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Eur Urol 57(4):728-9, 4/2010.
3. Siefker-Radtke AO. Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure. Expert Rev Anticancer Ther 9(12):1701-3, 12/2009. PMID: 19954279.

Abstracts

1. Ho PL, Willis DL, Patil J, Tart K, Parikh S, Shah JB, Delacroix SE, Siefker-Radtke AO, Dinney CP, Pisters LL, Kamat AM,. Outcome of patients with clinically node-positive bladder cancer who undergo consolidative surgery after preoperative chemotherapy: MD Anderson Cancer Center experience. 2014 Genitourinary Cancers Symposium (#318), 1/2014.
2. Siefker-Radtke AO, Choi W, Melquist J, Shen Y, Kamat A, Matin S, Millikan R, Dinney CP, Czerniak BA, McConkey DJ. Gene expression profiling in the context of neoadjuvant chemotherapy with DDMVAC+B (dose dense methotrexate, vinblastine, doxorubicin, cisplatin, and bevacizumab) can predict clinical outcomes and tumor biology. AACR 2014 Meeting (#CT241), 2014.
3. Siefker-Radtke AO, Wen S, Shen Y, Stigall K, McConkey DJ, Millikan RE. A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC). 2013 ASCO Annual Meeting (#4548), 2013.
4. Dinney CPN, Choi W, Porten SP, Roth B, Cheng T, Willis DL, Tran MN, Lee IC, Bondaruk JE, Majewski T, Zhang S, Pretzsch SM, Baggerly KA, Siefker-Radtke AO, Czerniak B, McConkey DJ. A STAT3- and p63-dependent transcriptional network to define a lethal basal subset of human bladder cancers. 2013 ASCO Annual Meeting (#4538), 2013.
5. Pagliaro LC, Munsell MF, Harris D, Carolla RL, Siefker-Radtke AO. Gemcitabine, paclitaxel, and doxorubicin as first-line therapy for patients with advanced urothelial carcinoma and renal insufficiency: A phase II study. 2013 ASCO Annual Meeting (#4528), 2013.
6. Willis DL, Fernandez M, Dickstein RJ, Parikh S, Siefker-Radtke AO, Guo C, Czerniak B, Shah JB, Pisters LL, Grossman HB, Dinney CPN, Kamat AM. Outcome of patients with micropapillary bladder cancer treated with neoadjuvant therapy and radical cystectomy. 2013 ASCO GU Symposium (#318), 2013.
7. Porten SP, Siefker-Radtke AO, Kamat AM, Dinney CPN, Matin SF. Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma. 2013 ASCO GU Symposium (#311), 2013.
8. PortenS, Siefker-Radtke AO, Kamat A, Dinney C, Matin S. Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma. AUA 2013 Meeting (#889), 2013.
9. Aparicio A, Sun J, Tang DN, Arap W, Araujo J, Corn P, Tannir N, Wang X, Siefker-Radtke AO, Sharma P. A phase II study of ipilumimab plus androgen deprivation therapy in castraton-sensitive prostate carcinoma. AACR 2012 meeting (#5368), 2012.
10. Dayyani F, Munsell MF, Siefker-Radtke AO. Incidence of peritoneal carcinomatosis in recurrent plasmacytoid urothelial carcinomas (PUC) of the bladder: A retrospective analysis of patient outcomes at M. D. Anderson Cancer Center (MDACC). 2012 ASCO Annual Meeting (#297), 2012.
11. Siefker-Radtke AO, Kamat AM, Corn PG, Matin SF, Grossman HB, Millikan RE, Dinney CPN. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M.D. Anderson Cancer Center. 2012 ASCO GU Symposium (#261), 2012.
12. Siefker-Radtke AO, Kamat AM, Corn PG, Matin SF, Grossman HB, Millikan RE, Dinney CPN. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the University of Texas M. D. Anderson Cancer Center. 2012 ASCO Annual Meeting (#4523), 2012.
13. Grivas P, Agarwal N, Siefker-Radtke, AO, Daignault S, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Smith DC, Hussain M. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). 2012 ASCO Annual Meeting (#4506), 2012.
14. Navai N, Williams MB, Wen S, Siefker-Radtke AO, McConkeyDJ, Dinney CPN, Adam L. Relationship between high microRNA-200C expression and the risk of death from disease in muscle-invasive urothelial carcinoma of the bladder. 2012 Genitourinary Cancers Symposium (#279), 2012.
15. Pagliaro LC, Munsell M, Harris D, Carolla RL, Siefker-Radtke AO. Gemcitabine, paclitaxel and doxorubicin for patients (pts) with urothelial carcinoma (UC) and renal insufficiency: Preliminary results of a multicenter phase II study. 2011 ASCO GU Symposium (#246), 2011.
16. Choi W, Shah JB, Tran M, Svatek RS, Marquis L, Lee IC, Yu D, Adam L, Bondaruk JE, Wen S, Shen Y, Dinney CPN, Czerniak B, McConkey DJ, Siefker-Radtke AO. Use of P63 expression to define a lethal subset of muscle-invasive bladder cancers. 2011 ASCO Annual Meeting (#4653), 2011.
17. Siefker-Radtke A, Margulis V, Kamat A, Grossman B, Wood C, Millikan R, Dinney C, Matin S. Evidence for neoadjuvant chemotherapy for high-grade upper-tract urothelial cancer: a retrospective review from the M. D. Anderson Cancer Center. 2010 ASCO GU Symposium(282), 2010.
18. Lynch SP, Vu TT, Kamat, AM, Grossman HB, Millikan RE, Dinney CP, Siefker-Radtke AO. The Impact of neoadjuvant chemotherapy in small cell carcinoma of the bladder: The MD Anderson Cancer Center experience. 2010 ASCO Annual Meeting (#4566), 2010.
19. Shah JB, Marquis LM, Svatek RS, Papadopoulos JN, Siefker-Radtke A, Dinney CP, McConkey DJ. The mitiotic spindle apparatus inhibitor AZD4877 holds promise as a novel therapeutic option against human bladder cancer. 2009 ASCO GU Symposium (#254), 2009.
20. Nguyen JM, Shah JB, Svatek RS, Siefker-Radtke AO, Dinney CP, McConkey DJ. The SRC inhibitor AZD0530 induces growth inhibition and migratory arrest of human bladder cancer cell lines. 2009 ASCO GU Symposium (#263), 2009.

Book Chapters

1. Siefker-Radtke AO. Targeted Therapy in Urothelial Cancer. In: Handbook of Targeted Cancer Therapy. Wolters Kluwer Health: USA, 2014.
2. Svatek RS, Kamat AM, Siefker-Radtke A, Dinner CPN. Bladder Cancer. In: 60 Years of Survival Outcomes at The University of Texas M. D. Anderson Cancer Center. 12. Ed(s) Rodriguez, M. Alma; Walters, Ronald S.; Burke, Thomas W. (Eds.). Springer, 2012. ISBN: 978-1-4614-5196-9.
3. Ng C, Siefker-Radtke A, Kamat A. Bladder Cancer and Upper Tracts. In: Oncologic Imaging: A Multidisciplinary Approach. Ed(s) PM Silverman. Elsevier: Philadelphia, 311 - 333, 2012. ISBN: 978-1-4377-2232-1.
4. Siefker-Radtke A. Chemotherapy, Surgical and Radiation Options for Metastatic Bladder Cancer. In: Essentials and Updates in Urinary Oncology. Ed(s) PE Spiess, M Biagioli, M Fishman, J Lockhart, WJ Sexton. Nova Science: USA, 2012. ISBN: 978-1620814949.
5. Efstathiou J, Quinn DI, Stenzl A, Bellmunt J, Cookson MS, Gakis G, Guru K, Heidenreich A, Keegan P, Lerner SP, Messing EM, Sagalowsky AI, Schoenberg MP, Shipley WU, Siefker-Radtke. Muscle-invasive, Presumably Regional, Tumor. In: Bladder Cancer, Second Edition. Ed(s) M Soloway, S Khoury. European Association of Urology: France, 269 - 342, 2012. ISBN: 978-9953-493-20-6.
6. Parwani A, Dinney C, Siefker-Radtke A. Small Cell Urothelial Carcinoma. In: The Urinary Tract. Ed(s) DE Hansel, JK McKenney, AJ Stephenson, SS Chang. Springer Publishers, 2012. ISBN: 978-1-4614-5319-2.
7. Siefker-Radtke A, Czerniak B, Dinney C, Millikan RE. Uncommon Cancers of the Bladder. In: Textbook of Uncommon Cancer, 4th. Ed(s) Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, Mayer IA. John Wiley and Sons, 2012.
8. Siefker-Radtke, AO, Dinney CPN, Czerniak, B, Millikan RE. Bladder Cancer. In: The MD Anderson Manual of Medical Oncology, 2nd. Ed(s) Kantarjian H, Wolff R, Koller C. McGraw Hill Medical, 925 - 943, 2011.
9. Siefker-Radtke AO, Dinney CP, Czerniak B, Millikan RE. Bladder Cancer. In: The MD Anderson Manual of Medical Oncology, 1st. McGraw-Hill, 739-756, 2006.
10. Siefker-Radtke A, Czerniak B, Dinney C, Millikan RE. Uncommon Cancers of the Bladder. In: Textbook of Uncommon Cancer, 3rd ed. Ed(s) Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, Mayer IA. John Wiley and Son, 2006.

Grant & Contract Support

Title: SPORE in Genitourinary Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Colin P. Dinney
Duration: 9/1/2011 - 8/31/2016
 
Title: Targeted Therapy in Bladder Cancer
Funding Source: AstraZeneca
Role: Co-Principal Investigator
Principal Investigator: David McConkey
Duration: 1/1/2010 - 12/31/2010
 
Title: Targeting the erbB Family in Bladder Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: David McConkey
Duration: 7/1/2008 - 6/30/2013
 
Title: Biology and Therapeutic Targeting of Epidermal Growth Factor Receptor in Bladder Cancer
Funding Source: NIH/NCI
Role: Clinical Co-Leader
Principal Investigator: Colin P Dinney
Duration: 9/25/2006 - 8/31/2012

Last updated: 8/8/2014